Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775831 | 0.86 | KCNH2 (0.41) | KCNH2ADORA2ASLC5A1JAK2KDM1A | |
| SCHEMBL16785576 | 0.84 | HTR2A (0.41) | SMN1; SMN2FYN | |
| SCHEMBL19365596 | 0.83 | ADORA2A (0.39) | KCNH2ADORA2ASLC5A1JAK2KDM1A | |
| SCHEMBL16785582 | 0.83 | ADORA2A (0.37) | ADORA2ASLC5A1JAK2KDM1AFYN | |
| SCHEMBL16785537 | 0.83 | SCN9A (0.39) | KCNH2ADORA2ASLC5A1JAK2KDM1A | |
| SCHEMBL16776478 | 0.83 | SCN9A (0.39) | KCNH2ADORA2ASLC5A1JAK2KDM1A | |
| SCHEMBL16775854 | 0.82 | SLC5A1 (0.37) | SLC5A1JAK2KDM1ASMN1; SMN2FYN | |
| SCHEMBL16775990 | 0.82 | ADORA2A (0.39) | ADORA2A | |
| SCHEMBL16776479 | 0.81 | SLC5A1 (0.41) | SLC5A1JAK2SMN1; SMN2NTRK1FYN | |
| SCHEMBL16776472 | 0.81 | CA2 (0.41) | ADORA2ASLC5A1JAK2KDM1AFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KCNH2 4052/4885ADORA2A 2325/4885SLC5A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.